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To better understand the pathogenetics of pseudoxanthoma elasticum (PXE), we performed a mutational analysis
of ATP-binding cassette subfamily C member 6 (ABCC6) in 122 unrelated patients with PXE, the largest cohort
of patients yet studied. Thirty-six mutations were characterized, and, among these, 28 were novel variants (for a
total of 43 PXE mutations known to date). Twenty-one alleles were missense variants, six were small insertions
or deletions, five were nonsense, two were alleles likely to result in aberrant mRNA splicing, and two were large
deletions involving ABCC6. Although most mutations appeared to be unique variants, two disease-causing alleles
occurred frequently in apparently unrelated individuals. R1141X was found in our patient cohort at a frequency
of 18.8% and was preponderant in European patients. ABCC6del23–29 occurred at a frequency of 12.9% and
was prevalent in patients from the United States. These results suggested that R1141X and ABCC6del23–29 might
have been derived regionally from founder alleles. Putative disease-causing mutations were identified in ∼64% of
the 244 chromosomes studied, and 85.2% of the 122 patients were found to have at least one disease-causing
allele. Our results suggest that a fraction of the undetected mutant alleles could be either genomic rearrangements
or mutations occurring in noncoding regions of the ABCC6 gene. The distribution pattern of ABCC6 mutations
revealed a cluster of disease-causing variants within exons encoding a large C-terminal cytoplasmic loop and in
the C-terminal nucleotide-binding domain (NBD2). We discuss the potential structural and functional significance
of this mutation pattern within the context of the complex relationship between the PXE phenotype and the function
of ABCC6.
Introduction
Pseudoxanthoma elasticum (PXE [MIM 177850 and
MIM 264800]) is a heritable disorder characterized by
dermal, vascular, and ocular lesions that result from the
accumulation of morphologically abnormal and min-
eralized elastic fibers in these tissues (Uitto and Shamban
1987). The skin manifestations are the most prevalent
characteristic of PXE and generally are the first physical
signs of the developing disorder. These skin changes are
often detected during childhood or adolescence, and they
progress slowly and unpredictably during adulthood.
The accumulation of abnormal calcified elastic fibers in
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the middermis produces typical skin lesions, which con-
sist of yellowish papules and plaques and of laxity with
loss of elasticity. These lesions are primarily seen on the
neck, axilla, antecubital fossa, groin, and periumbilical
area (Uitto and Shamban 1987; Neldner 1988; Uitto et
al. 1998). The diagnosis of PXE is confirmed histolog-
ically by the demonstration, in biopsies of lesional skin,
of fragmented calcified elastic fibers, by use of the Ver-
hoeff–van Gieson and von Kossa stains. Similar elastic
fiber changes within the internal elastic lamina of me-
dium-sized arteries are most frequently associated with
intimal fibroplasia and early onset of peripheral vascular
occlusive disease (Nishida et al. 1990; Lebwohl et al.
1993). Retinal angioid streaks, the other hallmark of
PXE, result from fragmentation and calcification of the
elastic component of the Bruch’s membrane. Angioid
streaks are associated with subretinal neovascularization
and hemorrhage, which can lead to disciform scarring
and severe loss of central vision (Weenink et al. 1996).
In addition to elastic fiber alterations, the abnormal dep-
osition of several other extracellularmatrix components,
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such as collagen fibrils and proteoglycan, has also been
demonstrated in tissue from patients with PXE (Bac-
carani-Contri et al. 1996; Passi et al. 1996).
PXE was first observed in 1881 (Rigal 1881) but was
not formally identified as a heritable disorder until 1896
(Darier 1896). Despite an abundant literature after these
initial reports, particularly in the last two decades, the
genetic basis of PXE remained entirely unknown until
recently. The PXE gene was first mapped to a 3–5-cM
locus at 16p13.1 (Struk et al. 1997; van Soest et al.
1997). This locus was then refined to a region of ∼500
kb (Le Saux et al. 1999; Cai et al. 2000) that contains
five candidate genes. Mutational analysis of all these
candidate genes led several groups to identify the first
mutations responsible for PXE in a gene that encodes
an ATP-binding cassette (ABC) subfamly C member 6
(ABCC6) transporter, also known as “multidrug resis-
tance–associated protein 6” or MRP6 (Bergen et al.
2000; Germain et al. 2000; Le Saux et al. 2000; Ring-
pfeil et al. 2000; Struk et al. 2000). ABCC6 consists of
31 exons spanning ∼75 kb and encodes a 165-kD trans-
membrane protein. The ABCC6 gene is predomi-
nantly expressed in both the liver and kidney. In a
recent study, ABCC6 has been localized to the ba-
solateral surface of hepatocytes (Madon et al. 2000).
Although ABCC6 is a typical ABC transporter, we do
not yet knowwhat molecule(s) this transmembrane pro-
tein transports. Similarly, the relationship between ab-
errant ABCC6 activity and extracellular changes in PXE
tissues remains to be elucidated.
To date, a limited number of apparently recurrent and
unique mutations of ABCC6 have been identified in
unrelated patients with PXE. To ascertain whether these
preliminary findings are indicative of a larger spectrum
of ABCC6 mutations and to determine, in particular,
whether the nature of these mutations may provide any
indication of the relationship of ABCC6 function to the
PXE phenotype, we performed a mutational analysis
(described in the present article) of ABCC6 in 122 un-
related patients with PXE, the largest cohort of such
patients yet studied, as a prerequisite to an elucidation
of the pathogenic mechanisms of PXE.
Patients, Material, and Methods
Patients
DNA samples from patients examined in the present
study were collected in the United Kingdom by F.M.P.,
in the United States and South Africa by S.T. and L.B.
(on behalf of PXE International, Inc.), in Italy and Ger-
many by I.P.R., and in Belgium by A.D.P. The diagnosis
of PXE in all unrelated patients was consistent with
consensus criteria reported elsewhere (Christiano et
al. 1992). The affected status of a patient was deter-
mined on the basis of examinations of dermal lesions
and the presence of ocular and/or cardiovascular find-
ings, and the status was confirmed by the observation
of calcified elastic fibers during histologic examination
of a skin biopsy specimen treated with von Kossa stain.
Genomic DNA obtained from a panel of 100 unrelated
and unaffected individuals was used for control pur-
poses. The panel comprised white individuals with or-
igins in Europe or the United States. All blood samples
were obtained from unaffected individuals and from pa-
tients who gave informed consent according to protocols
approved by the appropriate institutional review board
(or equivalent committee for human subjects in countries
other than the United States). Genomic DNA was iso-
lated from EDTA-anti-coagulated whole blood and was
purified with a QIAamp blood kit (Qiagen), according
to the manufacturer’s instructions. Purified DNA was
stored at 80C in a mixture (pH 8.0) of 1 mM Tris-
HCl and 0.1 mM EDTA.
PCR and DNA Sequence Analysis
Intron-derived primers for PCR amplification of all
31 ABCC6 exons were synthesized using sequence
information obtained from BAC clone CIT987SK-A-
962B4 (GenBank accession number U91318). Intron/
exon boundaries were deduced from information avail-
able in the Institute for Genome Research database and
by comparison with the ABCC6 cDNA (GenBank ac-
cession number NM_001171). Typical PCR reactions,
which have been described elsewhere (Le Saux et al.
1999), were performed in the presence of [32P]-labeled
primers in a 9700 thermocycler (PerkinElmer). PCR
products were 150–550 bp and included complete in-
tron/exon boundaries. Radioactive PCR products were
analyzed either by single-stranded conformation poly-
morphism (SSCP) analysis (Orita et al. 1989) using
MDE-PAGE (BioWhittaker Molecular Applications),
according to the manufacturer’s instructions, and by
conformation-sensitive gel electrophoresis (CSGE) anal-
ysis, as described elsewhere (Ganguly et al. 1993). DNA
conformers were eluted in water from gel slices and were
reamplified and sequenced with the same primers used
to generate the PCR products. Alternatively, PCR prod-
ucts were amplified directly from genomic DNA before
sequencing. DNA sequence analysis was performed us-
ing ABI BigDye terminator cycle sequencing with an ABI
310 automated DNA sequencer. The information gen-
erated by the sequencer was analyzed using the ABI
Prism genetic analyzer software, version 1.2.2. The Se-
quencher 3.1 program was used to identify variations
between the sequences of putative mutations and control
DNA.
Definition of Disease-Associated Alleles
For the purposes of this study, we have defined a se-
quence variant as phenotype-modifying (i.e., causative
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of PXE) by using criteria described elsewhere for defining
a nucleotide sequence variant as disease causing (Cotton
and Scriver 1998): (1) ABCC6 sequence variants pre-
dicted to result in nonsense or splice-site alterationswere
categorized as disease-associated alleles. These sequence
variants included premature stop codons, small and
large insertions/deletions resulting in a frameshift, and
sequence alterations within ABCC6 that had the poten-
tial to affect constitutive intron/exon splicing. To be con-
sidered as causative alleles, these sequence variants were
required to be absent in a panel of 200 alleles from
unaffected and unrelated control individuals. (2) Other
potentially pathogenic nucleotide variants resulting in
amino acid substitution were considered as disease-caus-
ing when (a) the substitution involved a conserved amino
acid, (b) the variant was absent in a panel of 200 alleles
of unaffected control individuals, and (c) the variant was
shown to cosegregate with the PXE phenotype in avail-
able kindreds. Conserved amino acids were identified on
the basis of an alignment of nine human ABCC proteins,
performed with the ClustalW program. The term “mu-
tation,” in the present article, refers to a putative disease-
causing allele defined according to these criteria. All ex-
onic and intronic changes that did not meet these criteria
were regarded as neutral or silent variants.
Haplotype Analysis
Microsatellite markers described elsewhere (Le Saux
et al. 1999) were used for high-resolution mapping of
chromosome 16p13.1. Each microsatellite was amplified
by PCR, using primers end-labeled with g[32P]-ATP. The
radiolabeled PCR products were analyzed by autora-
diography after electrophoresis on 6% polyacrylamide
gels containing 6 M urea, 37.5% formamide, and a buf-
fer containing 0.09 M Tris, 0.09 M boric acid, and 0.01
M EDTA. Electrophoresis was conducted at 80 W for
4–6 h, and gels were then dried and exposed to Fuji X-
ray film at 80C.
PCR Characterization of Alu-Mediated Deletions
The characterization of large deletions involving exon
15 and exons 23–29 of ABCC6 was conducted using
PCR amplification of the regions of interest, with prim-
ers positioned within flanking introns. The initial char-
acterization of the deletions was performed with a com-
bination of existing primers used to amplify the coding
regions corresponding to exons 14, 16, 22, and 30.
These primers were ABCC6Ex14m, 5′-AGG AAG CTG
TTG CCA CAC at-3′; ABCC6Ex16a, 5′-GCG AGG
AAG TGG GAC TTT CA-3′; ABCC6Ex21m, 5′-GCC
TGA GGG TTA GGC ACA TA-3′; and ABCC6Ex30a,
5′-CAG GAC CCC TCC AGC TCT AA-3′. The primers
used to determine the precise boundaries of these dele-
tions were located 5′ and 3′ of Alu repeats in introns 14,
15, 22, and 29. The sequences of these primers were
ABCC6IVS15a, 5′-TGC TGA GGT TGA GAA ACC
CA–3′; ABCC6IVS14m, 5′-GGC TAA GCC ATG AGA
GCT TT-3′; ABCC6IVS29a, 5′-CTG TAG GCA GGT
CAT TCA AA-3′; and ABCC6IVS22m, 5′-TCC CCT
AAA GAT GGA GAG AT-3′.
Results
Mutational Screening and Analysis
ABCC6 was screened in a cohort of 122 apparently
unrelated patients with PXE from families with an
autosomal recessive mode of inheritance of the PXE
phenotype. Affected individuals originated from sev-
eral European countries (Belgium, Germany, Holland,
Italy, and the United Kingdom), South Africa, and the
United States. All exons of ABCC6 from patients and
available unaffected relatives were amplified by PCR.
The PCR products were analyzed by a combination
of SSCP, heteroduplex scanning, and direct sequencing
to detect single-base substitutions and small inser-
tions/deletions. In this cohort of patients with PXE,
we found a total of 36 different mutations according
to our strict criteria (see Definition of Disease-Asso-
ciated Alleles section). Among these, 8 mutations had
been described elsewhere, and 28 mutations were
novel. Mutations identified in the present study, to-
gether with previously published mutations, bring the
total number of known PXE mutations to 43. This
information is summarized in table 1.
Mutation-Detection Rate
The overall detection rate of disease-causing sequence
variants within the 244 chromosomes that we analyzed
was 63.9%. The detection rate was slightly lower
(58.9%) when patients from known consanguineous
and Afrikaner families, for which a founder effect is
suspected (Torrington and Viljoen 1991), were not in-
cluded. The mutation-detection rate was 54.3% for the
European cohort, 64.9% for the United States cohort
(table 2), and 85.3% in patients of Afrikaner origin.
Within the Afrikaner population, themutation-detection
rate was higher, because most alleles appear to be iden-
tical by descent (O.L.S., K.B., C.S., C.T., E.W.J., L.B.,
S.T., D.L.V., and C.D.B., unpublished data). In our co-
hort of 122 patients, 104 (85.2%) individuals were
found to have at least one disease-causing allele. Of
these, two ABCC6 mutant alleles were detected in 52
patients, one allele was found in 52 patients, and no
disease-associated allele could be identified in the 18 re-
maining subjects with PXE.
PXE Mutations
The most-prevalent mutations detected in the ABCC6
gene were missense substitutions (21 [58.3%]mutations,
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Table 1
ABCC6 Mutations in a Cohort of Patients with PXE
CHANGE IN
STATUSa ORIGIN(S)b EXON(S)c REFERENCE(S)Amino Acid Nucleotide
… 179–195del ht Belgium 2 Present study
… 938–939insT ch, ht SA, UK 8 Present study
N411K 1233TrG ht US 10 Present study
A455P 1363GrC Nd Nd 11 Uitto et al. (2001)
R518Q 1553GrA ch, ht Belgium 12 Present study, Uitto et al. (2001)
F568S 1703TrC ch US 13 Present study
… ABCC6del15 hm SA 15 Present study
… 1944del22 ht Holland 16 Bergen et al. (2000)
… 1995delG ht Germany 16 Present study
L673P 2018TrC ch SA 16 Present study
R765Q 2294GrA ht Germany 18 Present study
Y768X 2304CrA ch, ht SA 18 Present study
… 2322delC ht US 18 Present study
… 2542delG Nd Nd 19 Uitto et al. (2001)
… IVS211GrT ch US, Germany i-21 Present study, Uitto et al. (2001)
R1030X 3088CrT ht SA, UK 23 Present study
R1114P 3341GrC hm UK 24 Present study
S1121W 3362CrG ch Germany 24 Present study
R1138W 3412CrT hm Nd 24 Ringpfeil et al. (2000)
R1138P 3413GrC ch Germany 24 Present study
R1138Q 3413GrA ch UK, US 24 Present study, Ringpfeil et al. (2000)
R1141X 3421CrT All All 24 Present study and othersd
R1164X 3490CrT ch Germany, UK 24 Ringpfeil et al. (2001)
G1203D 3608GrA ch Germany 25 Present study
… IVS26-1GrA ch Belgium i-26 Present study, Ringpfeil et al. (2000, 2001)
Q1237X 3709CrT ch Belgium 26 Present study
… 3775delT ht, hm SA, US, Holland 27 Present study, Bergen et al. (2000)
V1298F 3892GrT ht US 28 Present study
T1301I 3902CrT ch Belgium 28 Present study
G1302R 3904GrA hm US 28 Present study
A1303P 3907GrC ch Belgium 28 Present study
R1314W 3940CrT hm US 28 Present study
R1314Q 3941GrA ch Germany 28 Present study
G1321S 3961GrA ht US 28 Present study
R1339C 4015CrT All SA, US 28 Present study, Struk et al. (2000)
Q1347H 4041GrC hm US 28 Present study
D1361N 4081GrA ch Germany 29 Present study
… 4104delC ch Belgium 29 Present study
R1398X 4192CrT ch Belgium 29 Present study
… ABCC6del23–29 ch US 23–29 Present study, Ringpfeil et al. (2001)
… 4220insAGAA ht Holland 30 Bergen et al. (2000)
I1424T 4271TrC ht US 30 Present study
… ABCC6del ht Holland all Bergen et al. (2000)
a Nd p not determined; hm p homozygote; ht p heterozygote; ch p compound heterozygote.
b UK p United Kingdom; US p United States; SA p South Africa; Nd p not determined.
c Exon indicates which exon(s) contains the mutation or is deleted by the mutation; i- p the intron that contains the
mutation.
d Bergen et al. (2000), Germain et al. (2000), Struk et al. (2000), and Uitto et al. (2001).
see table 1). Other ABCC6 mutant alleles included five
(13.9%) nonsense and six (16.7%) frameshift muta-
tions. Among these, four mutations involved the deletion
of a single nucleotide, one mutation was an insertion of
thymidine, and one mutation corresponded to the de-
letion of 17 bp. Two other mutations were predicted to
affect constitutive exon/intron splicing of ABCC6 pre-
mRNA, and two large out-of-frame deletions of 1.6 kb
and 16.4 kb were characterized (these mutations are
described in detail in the sections below). Each of the
two splice-site mutations and each of the two deletion
mutations each accounted for 5.6% of all mutations
detected in the present study. Although most of the mu-
tations reported here appear to be unique, a few disease-
causing variants have been found to occur frequently in
apparently unrelated individuals; R1141X was found at
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Table 2
Frequencies of Mutant Alleles Found in a Cohort of 101 Unrelated Patients with PXE
MUTATIONa
OVERALL EUROPE UNITED STATES
No. of
Alleles
Frequency
(%)
No. of
Alleles
Frequency
(%)
No. of
Alleles
Frequency
(%)
R1141X 38 18.8 33 28.4 3 4.1
ABCC6del23–29 26 12.9 5 4.3 21 28.4
IVS211GrT 7 3.5 4 3.4 3 4.1
G1302R 4 2.0 0 .0 4 5.4
A1303P 4 2.0 3 2.6 1 1.4
R1314W 3 1.5 0 .0 3 4.1
R518Q* 3 1.5 1 .9 1 1.4
3775delT* 3 1.5 2 1.7 0 .0
R1138Q 2 1.0 1 .9 1 1.4
V1298F 2 1.0 0 .0 2 2.7
R1339C 2 1.0 0 .0 2 2.7
Q1347H 2 1.0 0 .0 2 2.7
4104delC* 2 1.0 1 .9 0 .0
179–195del 1 .5 1 .9 0 .0
938–939insT* 1 .5 0 .0 0 .0
N411K 1 .5 0 .0 1 1.4
F568S 1 .5 0 .0 1 1.4
1995delG 1 .5 1 .9 0 .0
R765Q 1 .5 1 .9 0 .0
2322delC 1 .5 0 .0 1 1.4
R1030X* 1 .5 0 .0 0 .0
R1114P 1 .5 1 .9 0 .0
S1121W 1 .5 1 .9 0 .0
R1138P 1 .5 1 .9 0 .0
G1203D 1 .5 1 .9 0 .0
IVS261GrA 1 .5 1 .9 0 .0
Q1237X 1 .5 1 .9 0 .0
W1241C 1 .5 1 .9 0 .0
T1301I 1 .5 1 .9 0 .0
R1314Q 1 .5 1 .9 0 .0
D1361N 1 .5 1 .9 0 .0
R1398X 1 .5 1 .9 0 .0
G1321S 1 .5 0 .0 1 1.4
I1424T 1 .5 0 .0 1 1.4
? 83 41.1 52 44.8 26 35.1
MDR … 58.9 … 55.2 … 64.9
NOTE.—Forty-two alleles from founder-derived and consanguineous families are not in-
cluded in this table. The total number of alleles represented is 202; 116 alleles were of
European origin; 74 were of US origin; and 12 originated elsewhere.
a * p Allele also found in a group of 12 non-European/non–United States alleles; ? p
unknown allele; MDR p mutation-detection rate.
a frequency of 18.8%, and ABCC6del23–29 occurred
at a frequency of 12.9% (table 2) in our cohort of pa-
tients. Of a total of 244 chromosomes, 42 were not taken
into account in these calculations, because they were
derived from consanguineous families or from the foun-
der-derived Afrikaner population. Most individuals with
two mutant alleles were compound heterozygotes. In-
terestingly, alleles R1141X and ABCC6del23–29 were
found to occur at different frequencies when patient or-
igin was considered. R1141X was far more frequently
represented in the European cohort (33 [28.4%] of 116
alleles) than in the U.S. cohort of patients with PXE (3
[4.1%] of 74). Also, this nonsense mutation was une-
qually distributed among the European countries con-
sidered. Indeed, 15 of 26 Belgians, 8 of 15 Germans, 3
of 12 British, 2 of 6 Dutch, and 1 of 1 Italian carried
an R1141X allele in a homozygous, compound hetero-
zygous, or heterozygous state. In the U.S. cohorts, three
patients carried a single R1141X allele. Among the
South African patients, 2 of the 5 who were of British
ancestry had the nonsense mutation in the heterozygous
or compound heterozygous state, and 2 of the 17 of the
Afrikaner patients carried a heterozygous or compound
heterozygous R1141X. In contrast to the latter muta-
tion, ABCC6del23–29 was found to represent nearly
one-third (21 [28.4%] of 74 alleles) of the United States
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Figure 1 Localization of mutations causing PXE in ABCC6. A, The positions of mutations presented as either nucleotide changes or
amino acid substitutions are indicated with respect to the exon/intron structure of ABCC6. The asterisk indicates mutations that have been
described only by others. Boxes represent exons drawn approximately to scale. The number of every fifth exon is indicated. Unshaded boxes
show exons encoding elements of NBD1 and NBD2. B, Horizontal lines indicate three large deletions involving some or all ABCC6 exons. The
horizontal line with dashes depicts a large deletion involving all of ABCC6, with deletion breakpoints both upstream and downstream of
ABCC6. C, The predicted topology of ABCC6 contains three transmembrane domains: TMD0, TMD1, and TMD2, with five, six, and six
membrane-spanning segments, respectively. NBD1 and NBD2 are also indicated. The various domains of ABCC6 are approximately aligned
with the various exons encoding these regions.
alleles, whereas only 5 (4.3%) of 116 alleles analyzed
among European patients with PXE were identified as
ABCC6del23–29. The difference in frequency is statis-
tically significant (Fisher’s exact test; andPp .0004
.0014, respectively). The frequency of individuals ho-
mozygous for these two frequently occurring disease-
causing alleles (R1141X and ABCC6del23–29) was
observed to be in Hardy-Weinberg equilibrium in the
European and United States cohorts, respectively.
When previously published mutations and those re-
ported in the present study are taken together (a total
of 43 mutations), 36 substitutions and deletions (85.7%)
were predicted to affect the C-terminal half of the
protein. Fifteen mutations (35.7%) were notably clus-
tered within the C-terminal nucleotide-binding domain
(NBD2) (fig. 1), which is encoded by exons 28, 29, and
30. It is noteworthy that seven mutations (16.7%) were
located in exon 24, and three of these mutations were
predicted to influence the codon for a single residue,
R1138. Remarkably, approximately one-third (12) of all
mutations affected arginyl residues. Also, it is interesting
to note that all but two mutations (F568S and G1203D)
located in the last transmembrane domain were pre-
dicted to reside in cytoplasmic regions of ABCC6. Most
individuals in whom two mutant alleles were identified
were compound heterozygotes.
Small and large deletions, insertions, and nonsense
mutations (which accounted for 13 of the 36 mutations
characterized in the present study) were all predicted to
result in premature termination of translation andwould
therefore be pathogenic. Premature termination muta-
tions frequently result in the nonsense-mediated decay
(NMD) of mutant mRNA products and significantly re-
duce mutant transcript levels (Maquat 1996; Nagy and
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Table 3
Missense Neutral Variants Identified in the ABCC6 Gene in a Cohort of 122 Patients
CHANGE IN
STATUSa ORIGIN(S)b EXON(S)
NO. OF ALLELES/
PXE CHROMOSOMES
NO. OF ALLELES/
CONTROL CHROMOSOMEScAmino Acid Nucleotide
G61D 182GrA ht SA 2 1/244 0/200
G207R 619GrA ht Belgium 6 1/244 0/200
R265G 793ArG ht Belgium 7 1/244 0/200
K281Ed 841ArG ht, hm SA 8 5/8d Nd
I319Vd 955ArG ht, hm SA 8 5/8d Nd
N497K 1489CrA ht Belgium 12 1/244 0/200
V614A 1841TrC ht, hm All 14 200/244 163/200
H632Qd 1896CrA ht, hm SA, Belgium 15 17/24d Nd
L953H 2858TrA ht US 22 1/244 0/200
W1241C 3723GrC ht Germany 26 1/244 0/200
R1268Q 3803GrA ht All 27 23/244 31/200
a ht p heterozygote; hm p homozygote.
b SA p South Africa.
c Nd p not determined.
d Neutral variant characterized by sequencing only.
Maquat 1998; Frischmeyer and Dietz 1999). In some
cases, however, premature termination mutations can es-
cape NMD and result in a substantial amount of trun-
cated proteins. These mutations are often located close
to the end of the open reading frame (Nijbroek et al.
1995; Mickle et al. 1998; Nagy and Maquat 1998). Al-
ternatively, premature termination mutations could re-
sult in exon skipping. Such consequences have been de-
scribed in several inherited disorders, notably for cystic
fibrosis, which is caused by mutations in the ABCC7
gene (Dietz et al. 1993; Hull et al. 1994; Messiaen et
al. 1997). Because several premature termination mu-
tations in ABCC6 are located near both the 5′ and 3′
ends of the gene, the consequences of premature ter-
mination mutations should therefore be experimentally
assessed case by case. One nonsense mutation (R1141X)
that we have previously characterized in a homozygous
state was indeed associated with no detectable ABCC6
messenger in RNA samples obtained from skin fibro-
blasts (Le Saux et al. 2000), and the absence of any
ABCC6 mRNA is probably caused by NMD and would
result in a null allele. The consequence of the out-of-
frame deletion ABCC6del23–29 was recently investi-
gated (Ringpfeil et al. 2001). This mutation was shown
to result in the deletion of 1,213 nucleotides of the
mRNA, associated with a premature termination codon
in exon 30 that probably results in a truncated protein.
The splice-site mutations that we have identified were
also likely to cause disease, given that they would prob-
ably result in either exon skipping or activation of a
cryptic splice site that would lead to either a truncated
protein or an aberrant one. The putative splice-site mu-
tation 4041GrC is of particular interest, because it may
result in aberrant mRNA splicing in addition to an
amino acid substitution, (Q1347H). Indeed, the muta-
tion occurring at the last nucleotide of exon 28 at the
donor splice site lowered the splice-potential score (Sha-
piro and Senapathy 1987) from 92.1 to 78.6. Moreover,
an identical mutation in ABCC7 (CFTR [GenBank ac-
cession number NM_000492]), which is responsible for
cystic fibrosis, involved the same glutaminyl residue,
Q1291H (3873GrC), at the last nucleotide of exon 20
of the ABCC7 gene and resulted in a glutaminyl-to-his-
tidinyl residue substitution. RNA-based PCR analysis
revealed that Q1291H in the ABCC7 gene was also a
splice mutation. Both correctly and aberrantly spliced
mRNAs were produced from the Q1291H allele. The
incorrectly spliced product resulted from the use of a
nearby cryptic splice site (Jones et al. 1992). We predict
that a similar aberrant splice product could occur as a
consequence of the Q1347H mutation in ABCC6.
All missense mutations presented in tables 1 and 2
were considered pathogenic, because they were not
found in our control panel of 200 alleles and because
they involved residues conserved among all nine human
ABCC proteins.
Neutral Variants
Nucleotide changes in the ABCC6 gene that are pre-
dicted to result in amino acid substitutions and are cat-
egorized as neutral (non–disease-causing) variants are
reported in table 3. These neutral variants did not reveal
any clustering. Three of the neutral variants (K281E,
I319V, and H632Q) could not be detected by SSCP or
CSGE. These changes were identified only by nucleotide
sequencing of PCR conformers that contain other silent
changes (data not shown) or mutations. The frequencies
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of K281E, I319V, and H632Q in our PXE cohort and
control panel were, consequently, not assessed. Most of
the neutral variants were unique; however, two of these
alleles (V614A and R1268Q) were found at 81.9% and
9.4%, respectively, in the cohort of patients with PXE.
Characterization of Two Alu-Mediated Deletions
ABCC6del23–29.—A loss of heterozygosity of an
R1141X allele was detected in three affected children
of a two-generation family from the United States.
These affected individuals seemed homozygous for
R1141X; whereas the mother appeared to be hetero-
zygous for this allele, and the father appeared to have
two normal alleles. Haplotype analysis performed with
12 microsatellites on chromosome 16p13.1 (Le Saux et
al. 1999) indicated, however, a heterozygous carrier
status for the nonsense mutation of the three affected
offspring. These results suggested that the affected off-
spring in this family had inherited a single maternal
R1141X mutation and a paternally derived deletion in-
volving exon 24, thereby reducing the nonsense muta-
tion to hemizygosity in all three patients. Several poly-
morphic variants in exons 14 and 19, intron 25, and
the ABCC6 3′ untranslated region (UTR) (Le Saux et al.
2000) were subsequently analyzed by SSCP to determine
the extent of this deletion. The experiment revealed the
deletion in this family to be identical to a recently re-
ported Alu-mediated deletion of ABCC6 exons 23–29
in several apparently unrelated families (Ringpfeil et al.
2001). PCR analysis, using intron 21 and 30 primers
flanking the deletion breakpoints, confirmed the paternal
origin of this 16,415-bp deletion within this pedigree
(data not shown). We have not found this deletion mu-
tation in our control panel of 200 alleles. Moreover, we
observed a frequency of this deletion of 12.9% in our
cohort of patients with PXE (table 2).
ABCC6del15.—We observed a different out-of-frame
deletion in ABCC6 in a single family of Indian ancestry
originating from South Africa. This mutation was in-
ferred from unsuccessful attempts to use PCR to amplify
exon 15 of ABCC6 from an affected member of this
family, in an analysis in which all other ABCC6 exons
could successfully be amplified. Using PCR primers in
introns 13 and 16, we obtained a PCR product of ∼3.0
kb, significantly shorter than the 4.6-kb PCR product
obtained from a control amplification (fig. 2A and 2B).
We designed a new pair of primers flanking two AluSx
sequences present in introns 14 and 15. The patient-
derived PCR product obtained using these new primers
was ∼0.5 kb; when the same primers were used with
control DNA, the PCR product was 2.1 kb. Both sets
of PCR experiments indicated a 1.6-kb deletion within
ABCC6 that resulted in the loss of exon 15 (fig. 2A and
2B). Sequence analysis revealed a 1,583-nucleotide de-
letion that included all of exon 15 (ABCC6del15). The
breakpoint occurred within a 12-bp domain (fig. 2C)
flanked by two 26-bp Alu core sequences (Rudiger et al.
1995), suggesting an Alu-mediated deletion. This dele-
tion of exon 15 would result in a frameshift within the
ABCC6 mRNA synthesized from the mutant allele, sub-
stituting the first codon of exon 16 for a nonsense mu-
tation (TAA). If an ABCC6 protein were encoded from
this mutant allele, the resulting polypeptide would be
shortened by 880 amino acids and would lack both
nucleotide-binding domains (NBDs). A haplotype anal-
ysis of this Indian family, which was performed with
17 microsatellites spanning the region p13.1 of chro-
mosome 16, revealed a stretch of 12 consecutive homo-
zygous markers both paternally andmaternally inherited
in the affected daughters (fig. 3A). The homozygosity of
this region of chromosome 16 was in agreement with
the consanguineous nature of this family. The unaf-
fected sister, however, was heterozygous for this de-
leted allele and had inherited a maternal chromosome
that conferred her carrier status, which was confirmed
by PCR (fig. 3B). ABCC6del15 was not found in our
control panel of 200 alleles nor was this deletion ob-
served in any of the other 122 patients included in
the present study.
ABCC6 Pseudogenes
During the course of the present mutational analysis
of the ABCC6 gene, several sequence variants that we
detected seemed to be derived from possible duplicated
regions of 16p13.1 that could correspond to one ormore
ABCC6 pseudogenes. Indeed, a nucleotide substitution
in exon 9—that would result in a nonsense mutation
Q378X (1132CrT)—and a single insertion in exon 2
(196–197insT) were observed in all Afrikaner and sev-
eral European patients who had already been shown to
be homozygous or compound heterozygous for other
ABCC6 mutations. Moreover, all 26 affected and un-
affected individuals tested thus far were found to be
heterozygous for both these apparent mutations. Exons
2 and 9 of ABCC6 of 15 Afrikaner patients, 4 European
patients, and 3 unaffected control individuals were se-
quenced. Mutations 196–197insT and Q378X were
found to be randomly associated with all of the ho-
mozygous or compound heterozygous mutant alleles.
Because these mutations would lead to premature ter-
mination of translation, both Q378X and 196–197insT
were potentially disease-causing alleles. The high fre-
quency of these variants in our control population sug-
gested that these alleles were, perhaps, part of a pseu-
dogene. Indeed, BLAST searches of the draft of the
Human Genome sequence at Web sites of the National
Center for Biotechnology Information (NCBI) and Cel-
era revealed two pseudogenelike sequences on chro-
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Figure 2 Characterization of a homozygous deletion of ABCC6 exon 15 in a patient with PXE who was of Indian origin. A, PCR analysis
of the deletion mutation. The amplification of a region corresponding to exons 14, 15, and 16 using primers 14a and 16m with genomic DNA
from a control individual (lane 1) and from the Indian patient with PXE (lane 2) resulted in PCR products of 4.6 kb and 3.0 kb, respectively.
Using primers flanking Alu repeats present in intron 14 and 15 (IVS14a and IVS15m), we obtained PCR products of 2.0 kb and 0.5 kb from
the same control individual (lane 3) and the Indian patient with PXE (lane 4), indicating that a homozygous deletion of about 1.6 kb occurred
in the subject with PXE. The position of the primers used to PCR-amplify exon 15 are shown in panel B. B, Schematic representation of the
genomic region surrounding ABCC6 exon 15 in an unaffected individual (top) and in the Indian patient with PXE (bottom). The sequence of
the junction of the deleted allele is also shown. C, The highest sequence homology of the two Alu Sx repeats within intron 14 and 15 was
noted in a 12-bp region that contains the 1,583-bp deletion breakpoint (red). Nucleotide sequence denoted in green represents the 26-bp core
sequences flanking the breakpoint domain in intron 14 and 15.
mosome 16 that contained regions highly homologous
to ABCC6 exons 1–4 and exons 1–9, respectively.
The sequence divergence between these putative pseu-
dogenes and ABCC6 (absent in any published ABCC6
mRNA sequences) corresponded to several nucleotide
substitutions and insertions that we have detected in our
cohort of patients with PXE, including Q378X and 196–
197insT (table 4). Interestingly, three of these substitu-
tions—1171ArG (V39V), 190TrC/191GrA (W64Q)
and 189GrC (L63L)—were found in a homozygous
state, indicating that these alleles can be found both
in the pseudogenes and the parental ABCC6. The re-
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Figure 3 Haplotype analysis of a family with PXE of Indian ancestry originating from South Africa. A, The analysis was performed with
17 D16S polymorphic markers spanning ∼25 cM of 16p13.1. This analysis allowed the assignment of paternal and maternal chromosomes to
the three offspring in this pedigree. Markers indicated in bold correspond to a stretch of 12 microsatellites found in a homozygous state and
suggested consanguinity in this pedigree. B, The cosegregation of the deletion ABCC6del15 and the phenotype was verified using PCR ampli-
fication of genomic DNA from the family members. The deleted alleles generated a PCR product of 2,978 bp, whereas the PCR product derived
from the normal allele was 4,561 bp. Individuals I-1, I-2, and II-1 carried both normal and mutant alleles, and both affected individuals, II-2
and II-3, displayed a homozygous deletion.
gion homologous to exons 1–9 of ABCC6 was found
in the Celera database, but no location could be de-
duced. However, the region homologous to exons 1–4
was identified on a chromosome 16 working-draft seg-
ment in the NCBI database (GenBank accession num-
ber NT_010393) at 275 kb centromeric to the paren-
tal ABCC6 gene and 55 kb centromeric to the NPIP
gene (GenBank accession number XM_017612) (Le
Saux et al. 1999; Cai et al. 2000). However, this
pseudogene was not contained within a contig of
four overlapping BAC clones, 962B4, 13F4, 589H1,
and 256A9 (GenBank accession numbers, U91318,
AC002039, AC002045, and AC002492, respectively)
that cover ∼415 kb of genomic DNA that extends cen-
tromeric of the ABCC6 gene (Le Saux et al. 1999; Cai
et al. 2000). Moreover, the NCBI map of chromosome
16 currently reports at least nine gaps of unknown length
between ABCC6 and the putative pseudogene contain-
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Table 4
Nucleotide and Apparent Amino Acid
Changes Found in Two ABCC6
Pseudogenes
CHANGE IN
EXONAmino Acid Nucleotide
V39Va 117ArG 2
L63La 189GrC 2
W64Qa 190TrC/191GrA 2
… 196–197insT 2
A78T 232GrA 3
A158V 473CrT 4
S359S 1077ArG 9
Q378X 1132CrT 9
L381L 1141TrC 9
a Variants found in homozygous states.
ing exons 1–4. It is therefore likely that the ABCC6
pseudogene containing exons 1–4 is located in a prox-
imal region of chromosome 16 at a distance 1415 kb.
The sequence surrounding this pseudogene diverged
from ABCC6 at breakpoints located 3.4 kb 5′ of the
exon 1 homologous sequence and 4.4 kb 3′ of the exon
4 homologous sequence. The domain within the pseu-
dogene homologous to the 5′ UTR of ABCC6 contained
two deleted regions of 142 and 315 bp, located at 2.8
kb and 0.9 kb, respectively, from the exon 1 homologous
sequence.
Genotype-Phenotype Correlation
The clinical information of 11 patients with PXE from
Belgium and 15 from South Africa was available at the
time of the present study. Among the four Belgian pa-
tients with homozygous R1141X alleles, three had typ-
ical skin lesions, and all patients displayed moderate-to-
severe ocular involvement. In one patient the skin lesions
were very mild. Five South African patients carried ho-
mozygous R1339C alleles. They also presented typical
light-to-moderate skin lesions and moderate-to-severe
ocular symptoms. However, three of these patients with
PXE had light-to-severe cardiovascular abnormalities. In
the group of 17 patients who carried compound hetero-
zygous mutations, the skin lesions appeared typical in
most, with a significant variability in ocular and cardi-
ovascular findings. Although the severity of dermal and
ocular lesions seems to correlate moderately with the
age of the patients (as has been observed elsewhere
[Neldner 1988]), no specific correlation appears between
the phenotype and the type or position of the mutations.
Discussion
The present study describes the identification of a spec-
trum of mutations in PXE. Thirty-six mutations were
characterized, and, among these, 28 were novel variants.
Most mutations were missense variants. Indeed, 21 nu-
cleotide substitutions were predicted to result in an
amino acid change. In addition, we have detected six
small insertions or deletions, five nonsense mutations,
two nucleotide substitutions likely to involve aberrant
mRNA splicing, and two large deletions. Therefore, the
total number of PXE mutations known to date is 43.
Putative disease-causing mutations were identified in
∼64% of the 244 chromosomes studied in affected in-
dividuals, and at least one disease allele was found in
85.2% of affected individuals.
PXE Mutations
The high degree of allelic heterogeneity observed in
PXE was comparable to that of other autosomal re-
cessive diseases. Although most mutations observed
in ABCC6 were unique, two variants (R1141X and
ABCC6del23–29) occurred at a high frequency (table
2). Overall, both mutations were found to occur at sim-
ilar frequencies, 18.8% and 12.9%, respectively. How-
ever, when patient ancestries were considered, R1141X
was found to occur at a greater frequency in Europe,
whereas ABCC6del23–29 was preponderant in the
United States (table 2). Such high frequencies suggest
that these alleles are likely to be transmitted identical
by descent from common ancestral alleles. Seventy
percent of the individuals from the United States are
of European ancestry, with some patients and families
originating in the United Kingdom. Four of the five
ABCC6del23–29 alleles found in Europe were identi-
fied in British patients. It is therefore possible that the
ABCC6del23–29 alleles are copies of a foundermutation
that originated in the British Isles before the first wave
of immigrants to the New World, in spite of divergent
haplotypes encountered in several families with this
Alu-mediated deletion (Ringpfeil et al. 2001). It is in-
deed reasonable to expect a rapid haplotype diver-
gence in chromosomal regions extending ∼10 cM on
each side of the ABCC6 gene over a period of 1200
years. A similar hypothesis could explain the high fre-
quency of R1141X alleles in the European sample.
However, to demonstrate that the various R1141X
and ABCC6del23–29 alleles are identical by descent,
the analysis of additional microsatellite markers and
single-nucleotide polymorphisms within and in close
proximity to ABCC6 will be required.
The mutation-detection rate obtained in the present
study indicated that a significant number of mutations
escaped detection by SSCP and CSGE. However, the per-
centage of detected mutations is comparable to those in
similar PCR-based studies that have defined a spectrum
of mutations in ABCA4 (Lewis et al. 1999; Maugeri et
al. 1999; Rivera et al. 2000). Mutations in ABCA4,
which also encodes an ABC transporter, are responsible
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for Stargardt disease (Allikmets et al. 1997b) and reti-
nitis pigmentosa (Cremers et al. 1998; Martinez-Mir et
al. 1998), and they could also be a factor in age-related
macular degeneration (Allikmets et al. 1997a). To de-
termine whether our screeningmethodswere a limitation
in the mutation-detection rate, all 31 exons of ABCC6
were sequenced from seven patients who had one or no
mutant alleles identified. No additional pathogenic se-
quence alteration could be detected, suggesting that
other sequence variants could be involved in PXE. Such
sequence variants may include large deletions, duplica-
tions, and alterations of sequence within introns, within
the promoter domain, and within the 3′UTR of ABCC6.
All of these rearrangements would be undetected in our
PCR-based analysis of exonic regions. It is also possible
that the mutation-detection rate could have been af-
fected by the presence of patients who have mutated
alleles in a heterozygous state and who have developed
a partial phenotype (van Soest et al. 1997; Bacchelli et
al. 1999; Rubegni et al. 2000; Sherer et al. 2001). In
addition, our criteria for defining a disease allele in-
cluded the prerequisite that such an allele not be present
in 200 control chromosomes derived from unaffected
individuals. Because it is not unreasonable to expect the
occasional presence of disease alleles in a heterozygous
state among unaffected individuals, particularly for a
disease of predominantly recessive inheritance, this rule
probably led us to overlook true alleles predisposing to
the disease.
It is remarkable that the two large deletions found in
this study, ABCC6del23–29 and ABCC6del15, were me-
diated by the same type of Alu repeats (AluSX), both
containing a core sequence of 26 bp (Rudiger et al.
1995). The analysis of the noncoding regions of ABCC6
revealed a high proportion of repetitive elements (Ring-
pfeil et al. 2001), suggesting that this gene might be
susceptible to a significant level of genomic rearrange-
ments. Indeed, ABCC6 intronic sequences contained 38
AluSX repeats, of which 19 presented a 26-bp core se-
quence that was95% conserved. The presence of these
numerous repetitive sequences supports our hypothesis
that a significant fraction of undetected mutations (table
2) could derive from DNA rearrangements that have yet
to be characterized.
Mutation Clusters
The distribution pattern ofABCC6mutations showed
a cluster of disease-causing variants in a region of the
gene that encodes the C-terminal end of the protein (fig.
1), in contrast to the neutral variants, which appeared
to be evenly distributed (table 3). Indeed, most (36 of
43) mutations, including deletions, were located in the
second half of the gene, and, remarkably, 24 (56%) mu-
tations were located in exon 24 and NBD2, which is
encoded by exons 28–30 (fig. 1). The significance of this
apparent clustering of mutations in the NBD2 domain
is not known. However, 70% of all missense mutations
occur within two domains of ABCC6: a large cytoplas-
mic loop of 70 amino acids encoded by exon 24 and
NBD2 and only two missense mutations (L673P and
R765Q; see fig. 1) were located in NBD1. The over-
whelming number of substitutions detected in NBD2 in
patients with PXE suggests that the two NBDs of
ABCC6 are functionally nonequivalent. Moreover, the
clustering of missense mutations in NBD2 suggests that
altered function of this ATP-binding domain is critical
to the development of the PXE phenotype.
The distinct role of NBDs of several other ABC
transporters—such as ABCC7 (CFTR), ABCC8 (SUR1
[GenBank accession number NM_000352]), and, no-
tably, ABCC1 (MRP1 [GenBank accession number
XM_017599])—has been demonstrated (Szabo et al.
1999; Ueda et al. 1999; Gao et al. 2000; Nagata et
al. 2000; Aleksandrov et al. 2001). However, there
are some distinctive differences in the proposed mod-
els of channel and transport activities for these trans-
membrane proteins. The binding and hydrolysis of ATP
at NBD1 in ABCC7 and ABCC8 initiate channel activity.
In contrast, the functional model of ABCB1 (P-glyco-
protein [GenBank accession number NM_000927]) in-
volves the alternate use of NBD1 and NBD2, because
the two NBDs appear to be functionally equivalent (Ur-
batsch et al. 1995; Senior and Gadsby 1997). The sug-
gested transport mechanism of ABCC1, which presents
a high degree of identity with ABCC6 (44.6%), is ini-
tiated with the binding and hydrolysis of ATP at NBD2,
followed by the trapping of ADP (Gao et al. 2000; Hou
et al. 2000; Nagata et al. 2000). The energy released
from the hydrolysis of the nucleotide at NBD2 is used
for the active transport of a substrate. The transport
would result in a conformational change favorable to
ATP binding at NBD1. The hydrolysis of this ATPwould
then be used to return the pump to its initial confor-
mation (Hou et al. 2000). Mutational analysis of both
ABCC1 NBDs showed that mutations at NBD2 abol-
ished transport, whereas mutations in NBD1 only re-
sulted in the decrease of transport activity by ∼70%
(Gao et al. 2000; Hou et al. 2000). Because of the high
similarity with ABCC1, it would be reasonable to infer
a similar structure/function relationship for ABCC6.
Hence, mutations within or in close proximity to the
NBD2 Walker motifs of ABCC6 could abolish all trans-
port activity. The presence of 50% of all missense mu-
tations in NBD2 (exons 28, 29, and 30) is in good agree-
ment with this hypothesis. Furthermore, homozygous or
compound heterozygous mutations in NBD1 may not
contribute significantly to the development of the PXE
phenotype, because an intact NBD2 could sustain a re-
sidual transport activity (30%), which could be com-
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parable to the overall transport capacity of an asymp-
tomatic individual carrying a single disease-causing allele
(50%).
Of the five mutations in exon 24, four amino acid
substitutions involve a change in charged residues. On
the basis of observations that substitutions of charged
residues in the CL4 domain of ABCC7 (CFTR) resulted
in protein misprocessing, it is possible to infer that mu-
tations in exon 24 of ABCC6, which encodes an equiv-
alent domain, could interfere with the proper folding
of ABCC6 (Seibert et al. 1996). Missense mutations in
other ABCC6 domains, such as transmembrane regions
(A455P, F568S, and G1203D), could also affect the pro-
tein processing or its integration into the cytoplasmic
membrane. Moreover, the introduction of a prolyl res-
idue at position L673, which is one of the two substi-
tutions in NBD1, could, similarly, result in an incorrect
folding. Indeed, it has been suggested that the proper
folding of ABCC7 (CFTR) depends on the integrity of
NBD1 and on complex interactions between both NBDs
and their surrounding environment (Dalemans et al.
1991; Pollet et al. 2000).
Phenotype-Genotype Correlation
No significant correlation could be established be-
tween the clinical manifestations and disease-causing al-
leles of the 26 patients with PXE for whom this infor-
mation was available. The small size of this cohort may
be a factor in the lack of obvious relation between the
phenotype and genotype. Although the severity of the
phenotype seemed to be related to the age of the patients,
it appeared not to be mutation dependent. Indeed, the
mutations identified in these patients (premature ter-
mination mutations and missense mutations located in
NBD2) are all predicted to result in the complete loss
of ABCC6 function. It is therefore reasonable to assume
that PXE mutations predispose carriers to the typical
PXE clinical lesions, but the contribution of other fac-
tors—such as trauma, in the case of ocular lesions, and,
perhaps, diet or lifestyle—may determine the age at onset
and the severity of the clinical manifestations.
Mutations in genes encoding many of the ABC trans-
porters produce phenotypes consistent with the overall
functions of these different transporters (de Vree et al.
1998; Strautnieks et al. 1998; Brooks-Wilson et al. 1999;
Rust et al. 1999). In contrast, it is quite unclear how
mutations in ABCC6 will influence the assembly and
deposition of elastic fibers and the subsequent devel-
opment of the ocular, dermal, and vascular phenotype
of PXE. It has been shown recently that the liver and
kidney tissues express relatively abundant levels of
ABCC6 mRNA (Kool et al. 1999), and very recent im-
munolocalization studies have identified a basolateral
location for ABCC6 in both hepatocytes and renal ep-
ithelial cells (Madon et al. 2000). It is possible, therefore,
that an aberrant transport function of ABCC6 in the
kidney and/or the liver could precipitate secondary
changes in the dermis and the arterial wall that lead to
calcification of elastic fibers and the development of
PXE. Indeed, for this reason, Uitto and coworkers
(2001) have suggested that perhaps PXE is more a her-
itable metabolic disorder than a connective tissue dis-
ease. Alternatively, altered renal and hepatic ABCC6
function may be of little consequence to PXE, and subtle
changes in the expression of this ABC transporter in the
tissue affected in patients with PXE may be instrumen-
tal in influencing an appropriate extracellular matrix
environment for the correct assembly of elastic fibers.
Although the substrate transported by ABCC6 is un-
known, a comparison with other ABCC transporters
suggests that it is unlikely that calcification of elastic
fibers in the tissue of patients with PXE results from
direct changes in calcium transport by ABCC6. Gluta-
thione conjugates of simple or complex anions are
thought, in general, to be the substrates for ABCC6,
and the continuing work to identify these substrates
will certainly provide valuable insight into the func-
tional relationships between ABCC6 and the complex
PXE phenotype.
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